Eli Lilly & Co. closed 20.65% short of its 52-week high of $972.53, which the company achieved on August 22nd.

While Leerink still expects Zoetis to post revenue and earnings growth, it sees the pace decelerating as rivals like Elanco and Merck (NSE: PROR) gain share. The firm forecasts Zoetis EPS growth to ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite ...

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

In a report released yesterday, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Merck & Company, with a price target of $83.00. The company’s shares closed yesterday at $83.71.

The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chro ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Global immunotherapy drugs market is valued at approximately USD 247.44 billion in 2023 and is projected to grow at a healthy CAGR of 15.3% over the forecast period 2024-2032. Request To Download Free ...

Total aggregate value of the drugs generating the highest sales in 2024 rose 6.5% vs. 2023, and jumped 53% over five years.